Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Could Seek New Indication For Iressa In Europe

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February

You may also be interested in...

AstraZeneca’s Iressa Produces Effect In Subpopulation, ASCO Data Show

Results of an initial Phase II study aimed at identifying responders to AstraZeneca's non-small cell lung cancer agent Iressa suggest further research could support approval in a subpopulation, researchers said at the recent American Society of Clinical Oncology meeting in Orlando, Fla

Targeted Oncologics Require Individualized Tumor Characterization – Amgen

Symbicort NDA On-Track, Exanta Decision Set For Second-Half – AstraZeneca

AstraZeneca will submit additional data for Symbicort inhalation delivery device. Hold-up comes in wake of setbacks for Iressa, Exanta and Crestor





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts